Selected features from HIVresistanceWeb past and present.
|
Interpreting Genotypic Resistance Tests
(March 2002)
"Imagine if the interpretation of a biopsy of a possible malignant tissue was different in different laboratories…" Robert W. Shafer, M.D. and Jonathan M. Schapiro, M.D. examine the interlaboratory discordance of genotypic HIV drug resistance test reports and review comparative approaches to identifying the best rules for genotypic interpretation.
|
Structured Treatment Interruption: Novel Strategy or Oxymoron?
(April 2001)
What do we know about STI in HIV infection? Brian Conway, M.D. and David Katzenstein, M.D. review the latest findings regarding this strategy in acute and chronic infection.
|
Kaletra: Sorting Fact from Fiction
(June 2001)
The durability of antiretroviral activity is dependent on interrelated patient, drug and virus factors. Brian Conway, M.D. reviews the relative contributions of such factors to the promising resistance profile of Kaletra.
|
How We Know What We Know About HIV Drug Resistance
(October 2000)
Dr. Bob Shafer takes stock of what we currently know about drug resistance, where that knowledge comes from, and where it might lead us. This review focuses on the interpretation of genotypic resistance test results and the four sources of laboratory and clinical data that form the basis of drug resistance knowledge.
|
Clinical Information on Resistance Testing: New Clinical Trials and Improvements in Tests and Reports
(June 2001)
Michelle Roland, MD, reports on clinical and technological issues in HIV drug resistance testing.
|
